Indian pharmaceutical major Granules India announced from its Hyderabad headquarters that relocating large-scale generic drug manufacturing to the United States remains highly impractical due to steep domestic operating costs, despite proposed US import tariffs. Executive Director Priyanka Chigurupati stated that while the company is prepared to leverage its existing US facilities for flexibility, a wholesale shift of high-volume production is economically unviable. The announcement comes as global pharmaceutical supply chains brace for potential trade disruptions under proposed US tariff overhauls.<\/p>\n
The US generic drug market relies heavily on foreign manufacturers, with India supplying approximately 40 percent of the nation’s generic medicines, according to data from the Association for Accessible Medicines (AAM). Trade policymakers in Washington have increasingly floated aggressive tariff structures to incentivize domestic manufacturing and secure pharmaceutical supply chains. However, industry analysts argue that the cost of raw materials, labor, and regulatory compliance in the US makes localized mass production of low-margin generics nearly impossible without massive government subsidies.<\/p>\n
Chigurupati emphasized that the cost delta between manufacturing in India and the US is too wide for tariffs alone to close. “Large-scale generic manufacturing in the US is a very difficult proposition,” Chigurupati explained during an industry briefing. She noted that while tariffs are designed to level the playing field, the sheer capital expenditure and operational costs of running high-output formulation plants in the US would inevitably drive up drug prices for American consumers.<\/p>\n
Granules India is not entirely without domestic options, maintaining a state-of-the-art formulation research and development (R&D) and manufacturing facility in Virginia. This facility provides the company with a localized buffer and the operational agility to pivot certain product lines if tariff policies become punitive. However, Chigurupati expects the proposed tariff frameworks to undergo significant revisions and negotiations before implementation, mitigating some of the immediate pressure on foreign manufacturers.<\/p>\n
The company maintains a positive outlook on its business growth, driven by its strategic diversification. By focusing on vertically integrated operations, Granules controls its supply chain from active pharmaceutical ingredients (APIs) to finished dosages. This integration provides a significant cost advantage that independent US manufacturers struggle to replicate, shielding the company from some market volatility.<\/p>\n
Beyond trade policy, Granules is currently navigating critical regulatory milestones, including an upcoming US Food and Drug Administration (FDA) reinspection of its key Indian facilities. Passing these inspections is vital for maintaining the company’s export pipeline to the lucrative US market. The company remains optimistic about its compliance trajectory and its broader pivot toward high-margin complex generics, which are less sensitive to basic tariff pressures than standard small-molecule drugs.<\/p>\n
Complex generics, which include injectables and ophthalmic formulations, require advanced manufacturing capabilities and face less competition. By shifting its product mix toward these sophisticated therapeutics, Granules aims to absorb potential tariff penalties while maintaining robust profit margins. This strategy aligns with broader industry trends where generic drugmakers transition away from commodity-grade medicines to avoid price erosion.<\/p>\n
For the broader healthcare sector, a rigid enforcement of tariffs on essential medicines could trigger widespread drug shortages and inflation in the US healthcare system. Industry experts warn that US payers and patients could face higher co-pays if manufacturers are forced to pass tariff costs down the supply chain. Consequently, watchdogs expect intense lobbying from hospital networks and pharmaceutical distributors to exempt critical life-saving medications from any final tariff lists.<\/p>\n
The situation highlights the delicate balance between national security interests and public health affordability. While the US government seeks to reduce reliance on foreign suppliers, the immediate financial impact on patients remains a primary concern for policymakers. The trade-offs of localized production could force a reevaluation of how essential medicines are subsidized and regulated in Western markets.<\/p>\n
Moving forward, the industry will closely monitor the specific exemptions carved out in upcoming US trade bills and the final language of the tariff proposals. Additionally, the outcome of Granules’ pending FDA reinspection will serve as a key indicator of its near-term export capacity. Stakeholders will also watch how quickly Granules and its peers can scale their complex generic portfolios to hedge against geopolitical and trade policy risks.<\/p>\n","protected":false},"excerpt":{"rendered":"
Indian pharmaceutical major Granules India announced from its Hyderabad headquarters that relocating large-scale generic drug manufacturing to the United States remains highly impractical due to steep domestic operating costs, despite…<\/p>\n","protected":false},"author":1,"featured_media":2507,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5],"tags":[2709,642,2707,2708,88,2710],"class_list":["post-2506","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-insights","tag-drug-manufacturing-costs","tag-generic-drugs","tag-granules-india","tag-pharmaceutical-tariffs","tag-supply-chain","tag-us-fda"],"jetpack_publicize_connections":[],"_links":{"self":[{"href":"https:\/\/srkanalytics.com\/index.php?rest_route=\/wp\/v2\/posts\/2506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/srkanalytics.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/srkanalytics.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/srkanalytics.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/srkanalytics.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2506"}],"version-history":[{"count":0,"href":"https:\/\/srkanalytics.com\/index.php?rest_route=\/wp\/v2\/posts\/2506\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/srkanalytics.com\/index.php?rest_route=\/wp\/v2\/media\/2507"}],"wp:attachment":[{"href":"https:\/\/srkanalytics.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/srkanalytics.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/srkanalytics.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}